Answers are grounded in this paper and cite their sources.
Background Stroke-Associated Pneumonia (SAP) is one of the leading causes of sepsis and ICU mortality among stroke patients, attributed to dysregulated immune responses as well as multiple MODES of cell death. Jiajiang Xuming Decoction (JXD) is a traditional Chinese medicine (TCM) formula to treat the symptoms of Wind-Phlegm-Stasis Obstruction Syndrome, blamed for all SAP-related sepsis. Methods A single-centre retrospective cohort study was conducted in 100 ICU patients with microbiologically confirmed sepsis (Sepsis-3 criteria): 58 Stroke-Associated Pneumonia (SAP) and 42 non-SAP sepsis, compared to thirty healthy controls. On admission, Day 3 and Day 7, serial inflammatory markers (IL-6, IL-1β, TNF-α PCT CRP) and organ-function indicators were measured (hepatic: ALT AST; renal: creatinine (BUN); cardiac: cTnI† NT-proBNP). Therapeutic efficacy of JXD was evaluated in a propensity-score-matched (JXD n = 29; conventional treatment n = 29) sub-cohort. Mechanistic evidence were derived from scRNA-seq and an in vitro LPS + OGD cell model as well as ferroptosis characterisation (GEO: GSM5319987). Results Compared to non-SAP sepsis, SAP patients had significantly higher levels of inflammatory cytokines, markers of hepatic injury (ALT, AST), renal impairment (creatinine, BUN), and cardiac injury (cTnI, NT-proBNP) all P < 0.001; FDR q < 0.001). An AUC = 0.872 for SAP diagnosis with a combination of four markers (PCT + IL-6 + ALT + creatinine) was established. Supplemental JXD therapy provided a significant advantage over conventional treatment in Day-7 clinical improvement rate (72.4% vs. 48.3%, P = 0.048) and shortened ICU stay (12.1 vs. 16.3 days, P = 0.002), along with markers of mode microbiome-related inflammation and injury reduction in this population of patients with acute disturbances post-septic organs (Galluzzi et al., Cell Death Differ, 2018, 25(3), 486–541). JXD basically inhibited apoptosis (CASP3), pyroptosis (NLRP3), necroptosis (RIPK3) in vitro , and reversed ferroptotic death by restoring GPX4, downregulating MDA, as well as inhibiting ACSL4. Conclusion Multi-organ dysfunction biomarkers independently predicts sepsis sequelae post-SAP (AUC = 0.872)) and track treatments response Conclusions: JXD modulates a number of cellular death pathways in vitro , and markedly improves clinical outcomes in SAP-associated sepsis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: